showed in a NSCLC dataset that immune-related gene expression signatures M1 (CBLB, CCR7, CD27, CD48, FOXO1, FYB, HLA-B, HLA-G, IFIH1, IKZF4, LAMP3, NFKBIA, and SAMHD1) and a peripheral T cell signature (HLA-DOA, GPR18, STAT1) have predictive power for predicting clinical benefit. The gene discussed is IFIH1; the disease is non-small cell lung carcinoma.